Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways

Duane C. Hassane, Siddhartha Sen, Mohammad Minhajuddin, Randall M. Rossi, Cheryl A. Corbett, Marlene Balys, Liping Wei, Peter A. Crooks, Monica L. Guzman, Craig T. Jordan

Blood (2010) 116 (26): 5983–5990.

https://doi.org/10.1182/blood-2010-04-278044

Published: 2010

Includes: Supplemental data

Journal Articles

Chemical Genomic Screening Reveals That PI3K/mTOR Inhibition Enhances Activity of the Anti-Leukemia Stem Cell Compound Parthenolide.

Duane Hassane, Ph.D., Siddhartha Sen, Cheryl A Corbett, Marlene Balys, Randall M Rossi, Peter A Crooks, PhD, Monica L. Guzman, PhD, Craig T. Jordan, PhD

Blood (2009) 114 (22): 388.

https://doi.org/10.1182/blood.V114.22.388.388

Published: 2009

Journal Articles

Chemical Derivatives of the Anti-Leukemia Stem Cell Compound 4-Benzyl-2-Methyl-1,2,4-Thiadiazolidine-3,5-Dione (TDZD-8) with Improved Activity.

Monica L. Guzman, PhD, Shama Nasim, Marlene Balys, Cheryl A Corbett, Peter A Crooks, PhD, Craig T. Jordan, PhD

Blood (2009) 114 (22): 3764.

https://doi.org/10.1182/blood.V114.22.3764.3764

Published: 2009

Journal Articles

Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8)

Monica L. Guzman, Xiaojie Li, Cheryl A. Corbett, Randall M. Rossi, Timothy Bushnell, Jane L. Liesveld, Josée Hébert, Fay Young, Craig T. Jordan

Blood (2007) 110 (13): 4436–4444.

https://doi.org/10.1182/blood-2007-05-088815

Published: 2007

Includes: Supplemental data

Journal Articles

An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells

Monica L. Guzman, Randall M. Rossi, Sundar Neelakantan, Xiaojie Li, Cheryl A. Corbett, Duane C. Hassane, Michael W. Becker, John M. Bennett, Edmund Sullivan, Joshua L. Lachowicz, Andrew Vaughan, Christopher J. Sweeney, William Matthews, Martin Carroll, Jane L. Liesveld, Peter A. Crooks, Craig T. Jordan

Blood (2007) 110 (13): 4427–4435.

https://doi.org/10.1182/blood-2007-05-090621

Published: 2007

Includes: Supplemental data

NARROW

Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways

Chemical Genomic Screening Reveals That PI3K/mTOR Inhibition Enhances Activity of the Anti-Leukemia Stem Cell Compound Parthenolide.

Chemical Derivatives of the Anti-Leukemia Stem Cell Compound 4-Benzyl-2-Methyl-1,2,4-Thiadiazolidine-3,5-Dione (TDZD-8) with Improved Activity.

Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8)

An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells

Email alerts

ASH Publications

American Society of Hematology

Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways

Chemical Genomic Screening Reveals That PI3K/mTOR Inhibition Enhances Activity of the Anti-Leukemia Stem Cell Compound Parthenolide.

Chemical Derivatives of the Anti-Leukemia Stem Cell Compound 4-Benzyl-2-Methyl-1,2,4-Thiadiazolidine-3,5-Dione (TDZD-8) with Improved Activity.

Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8)

An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only